Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine

Condition:   Chikungunya Virus Infection Interventions:   Biological: MV-CHIK lyophilised formulation, low dose;   Biological: MV-CHIK liquid frozen formulation, low dose;   Biological: MV-CHIK SPS® formulation, low dose;   Biological: MV-CHIK liquid frozen formulation, high dose;   Biological: MV-CHIK liquid frozen formulation, high dose and placebo Sponsors:   Themis Bioscience GmbH;   Celerion;   Assign Data Management and Biostatistics GmbH Not yet recruiting

Source: ClinicalTrials.gov - August 17, 2018 Category: Research Source Type: clinical trials